Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360859 | 0.94 | CHRM3 (0.66) | CHRM3CHRM2SLC2A1 | |
| SCHEMBL1359832 | 0.93 | CHRM3 (0.60) | CHRM3CHRM2SLC2A1 | |
| SCHEMBL1361590 | 0.92 | CHRM3 (0.65) | CHRM3CHRM2SLC2A1 | |
| SCHEMBL1359955 | 0.92 | CHRM2 (0.71) | CHRM3CHRM2SLC2A1 | |
| SCHEMBL1360695 | 0.92 | CHRM2 (0.71) | CHRM3CHRM2SLC2A1 | |
| SCHEMBL1362067 | 0.90 | CHRM3 (0.62) | CHRM3CHRM2SLC2A1 | |
| SCHEMBL381227 | 0.88 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL381198 | 0.88 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL1359815 | 0.87 | CHRM3 (0.60) | CHRM3SLC2A1 | |
| SCHEMBL1359817 | 0.87 | CHRM3 (0.60) | CHRM3SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262205-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-08-28 | — | — | US | claimed |
| EP-1723112-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005087736-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2005-09-15 | — | — | US | claimed |
| US-8067439-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110059931-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-7851631-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070293461-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | disclosed |
| US-7262205-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059931-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885SLC2A1 4805/4885 |
| US-20050203131-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885SLC2A1 4805/4885 |
| US-20070293461-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885CHRM2 1/4885SLC2A1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.